181 related articles for article (PubMed ID: 16399769)
21. HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study.
Kelly RS; Patnick J; Kitchener HC; Moss SM;
Br J Cancer; 2011 Sep; 105(7):983-8. PubMed ID: 21897395
[TBL] [Abstract][Full Text] [Related]
22. Projected cost-effectiveness of repeat high-risk human papillomavirus testing using self-collected vaginal samples in the Swedish cervical cancer screening program.
Östensson E; Hellström AC; Hellman K; Gustavsson I; Gyllensten U; Wilander E; Zethraeus N; Andersson S
Acta Obstet Gynecol Scand; 2013 Jul; 92(7):830-40. PubMed ID: 23530870
[TBL] [Abstract][Full Text] [Related]
23. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
[TBL] [Abstract][Full Text] [Related]
24. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening.
Kitchener HC; Almonte M; Gilham C; Dowie R; Stoykova B; Sargent A; Roberts C; Desai M; Peto J;
Health Technol Assess; 2009 Nov; 13(51):1-150, iii-iv. PubMed ID: 19891902
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme.
Sherlaw-Johnson C; Philips Z
Br J Cancer; 2004 Jul; 91(1):84-91. PubMed ID: 15162150
[TBL] [Abstract][Full Text] [Related]
27. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
28. Cost and logistics of alternative roll-out options for implementing human papillomavirus testing as a triage in cervical screening: results of the sentinel sites study.
Legood R; Sadique Z; Patnick J; Kitchener H; Kelly R; Moss S
Br J Cancer; 2012 Oct; 107(9):1574-9. PubMed ID: 23037717
[TBL] [Abstract][Full Text] [Related]
29. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS).
Kulasingam SL; Kim JJ; Lawrence WF; Mandelblatt JS; Myers ER; Schiffman M; Solomon D; Goldie SJ;
J Natl Cancer Inst; 2006 Jan; 98(2):92-100. PubMed ID: 16418511
[TBL] [Abstract][Full Text] [Related]
31. Human papillomavirus testing with conventional Pap smear screening in three inner London community clinics.
Herbert A; Best JM; Chana P; Ktori E; Nowicki M; Dunsmore H; Culora G; Arbyn M; Kubba AA
J Fam Plann Reprod Health Care; 2007 Jul; 33(3):171-6. PubMed ID: 17609075
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus triage of women with persistent borderline or mildly dyskaryotic smears: Comparison of costs and side effects of three alternative strategies.
Rebolj M; Bais AG; van Ballegooijen M; Boer R; Meerding WJ; Helmerhorst TJ; Habbema JD
Int J Cancer; 2007 Oct; 121(7):1529-35. PubMed ID: 17565745
[TBL] [Abstract][Full Text] [Related]
33. MAVARIC - a comparison of automation-assisted and manual cervical screening: a randomised controlled trial.
Kitchener HC; Blanks R; Cubie H; Desai M; Dunn G; Legood R; Gray A; Sadique Z; Moss S;
Health Technol Assess; 2011 Jan; 15(3):iii-iv, ix-xi, 1-170. PubMed ID: 21266159
[TBL] [Abstract][Full Text] [Related]
34. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
35. Liquid-based cervical cytology using ThinPrep technology: weighing the pros and cons in a cost-effectiveness analysis.
de Bekker-Grob EW; de Kok IM; Bulten J; van Rosmalen J; Vedder JE; Arbyn M; Klinkhamer PJ; Siebers AG; van Ballegooijen M
Cancer Causes Control; 2012 Aug; 23(8):1323-31. PubMed ID: 22706692
[TBL] [Abstract][Full Text] [Related]
36. Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. HPV Effectiveness in Lowgrade Paps (HELP) Study No. 1 Group.
Lytwyn A; Sellors JW; Mahony JB; Daya D; Chapman W; Ellis N; Roth P; Lorincz AT; Gafni A
CMAJ; 2000 Sep; 163(6):701-7. PubMed ID: 11022584
[TBL] [Abstract][Full Text] [Related]
37. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
Tay SK; Lin LE; Goh RC
Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
[TBL] [Abstract][Full Text] [Related]
38. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
39. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial.
Ronco G; Cuzick J; Pierotti P; Cariaggi MP; Dalla Palma P; Naldoni C; Ghiringhello B; Giorgi-Rossi P; Minucci D; Parisio F; Pojer A; Schiboni ML; Sintoni C; Zorzi M; Segnan N; Confortini M
BMJ; 2007 Jul; 335(7609):28. PubMed ID: 17517761
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.
Berkhof J; Bulkmans NW; Bleeker MC; Bulk S; Snijders PJ; Voorhorst FJ; Meijer CJ
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1268-73. PubMed ID: 16835322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
